Price movement over the last 24 hours
ADMA Biologics Inc vs Utilities Select Sector SPDR Fund — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Utilities Select Sector SPDR Fund trades at $45.4. The key difference: Utilities Select Sector SPDR Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XLU | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $47.73 |
52-Week Low | $7.60 | $40.57 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XLU trades at $45.30, down 1.01% today, with a bullish technical signal supported by moving averages. The ETF provides pure exposure to US utilities, benefiting from AI-driven power demand growth. Recent news highlights utilities' role in powering AI data centers, with top holdings securing long-term clean energy agreements. Technical indicators show neutral oscillators but bullish ADX signals, with key support at $44-$45 and resistance at $46.
The outlook for XLU is positive due to structural demand growth from AI infrastructure, though valuation metrics are unavailable. Risks include interest rate sensitivity and regulatory uncertainty. Analyst sentiment is mixed, with utilities transitioning from bond proxies to growth plays amid rising power needs.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →